AbCellera has formed a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by the pharmaceutical partner.   “AbCellera continues to build its reputation as a high-powered innovation shop and the premier provider for therapeutic antibody discovery from natural immune responses. This partnership with Novartis marks an important...